The LRATD2 (Leucine-Rich Repeat and Transmembrane Domain-Containing 2) antibody is a tool used to study the LRATD2 protein, encoded by the *LRATD2* gene (also known as *C17orf59* or *TMEM2*). LRATD2 is a transmembrane protein characterized by leucine-rich repeats (LRRs), which are often involved in protein-protein interactions and cellular signaling. While its exact biological role remains under investigation, LRATD2 has been implicated in cancer biology, particularly in ovarian and breast cancers, where it may act as a tumor suppressor by regulating cell proliferation, apoptosis, or metastasis. Studies suggest its expression is downregulated in certain malignancies, correlating with poor prognosis. The LRATD2 antibody is primarily utilized in research applications such as Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression patterns in tissues or cell lines. It aids in exploring LRATD2's subcellular localization, interaction partners, and functional pathways. Recent work has also linked LRATD2 to cellular stress responses and mitochondrial function, though mechanistic insights are still emerging. Validation of this antibody includes specificity checks via knockout cell lines or siRNA-mediated knockdown. Its development supports ongoing efforts to elucidate LRATD2's role in disease pathogenesis and its potential as a therapeutic target or biomarker.